ClinConnect ClinConnect Logo
Search / Trial NCT01881516

Acupuncture Research on Lung Cancer Patients With Cancer Related Fatigue(CRF)

Launched by FUDAN UNIVERSITY · Jun 17, 2013

Trial Information

Current as of May 27, 2025

Unknown status

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who are pathologically/cytologically diagnosed as NSCLC and received radiotherapy with or without chemotherapy, and the last radio- or chemo-therapy must be at least 30 days prior to initiation of experimental treatment;
  • Participants who meet the diagnosis criteria of CRF(ICD-10 criteria);
  • The first time to receive acupuncture treatment;
  • The age is between 18 and 65 years old;
  • Mean baseline fatigue as measured by the Brief Fatigue Inventory (BFI) must be four or above;
  • ECOG performance status 0, 1 or 2.
  • Patients must have adequate organ functions reflected by the laboratory criteria below: neutrophil counts ≥ 1.5×109 /L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 85 g/L, Serum creatinine \< 2.0 mg/dL, Bilirubin \< 1.5 mg/dL, ALT \< 3 x normal, albumin \>30g/L.
  • Have not taken any hypnotic, melatonin, or antidepressants within 30 days;
  • Willing to finish the whole observation period;
  • With written consent form signed by themselves.
  • Exclusion Criteria:
  • Participants in other clinical research;
  • Can not be pathologically or cytologically diagnosed as NSCLC;
  • ECOG 3\~4;
  • Pregnant woman;
  • \>65 or \<18 years old;
  • Patients with evidence of any cognitive dysfunction that would limit their abilities to report fatigue;
  • Patients who have received acupuncture ever before;
  • Received surgery, immunotherapy or target therapy within one month before the recruition;
  • Taking warfarin or heparin, a bleeding tendency exists;
  • Infection, ulceration or hyperalgesia at or near the local acupoints' skin,or with active infections;
  • There are cerebral vascular accident history or spinal cord injury history;
  • Combination with other serious diseases or condition, including congestive heart failure, Unstable angina pectoris, myocardial infarction during the past six months, serious's arrhythmia, mental disorders, drug abuse, etc.;
  • Patients with a life expectancy \< 3 months;
  • Patients with a past history of therapy or scheduled visits non-compliance, as determined by their treating physician.

About Fudan University

Fudan University, a prestigious comprehensive research university located in Shanghai, China, is committed to advancing medical science through innovative clinical research. Renowned for its rigorous academic standards and cutting-edge research facilities, Fudan University plays a pivotal role in the global health landscape by sponsoring a diverse array of clinical trials aimed at improving patient outcomes and addressing pressing medical challenges. Leveraging its multidisciplinary expertise and collaborative networks, the university strives to translate scientific discoveries into practical applications, fostering advancements in healthcare and contributing to the well-being of communities both locally and internationally.

Locations

Patients applied

0 patients applied

Trial Officials

jing xie, MD

Principal Investigator

Fudan University

zhen chen, MD

Study Director

Fudan University

qiang zhi meng, MD

Study Chair

Fudan University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials